• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房颤动。

Atrial fibrillation.

机构信息

Department of Physiology, Amsterdam University Medical Centers, VU Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands.

Department of Physiology and Cell Biology, College of Medicine/Wexner Medical Center, The Ohio State University, Columbus, OH, USA.

出版信息

Nat Rev Dis Primers. 2022 Apr 7;8(1):21. doi: 10.1038/s41572-022-00347-9.

DOI:10.1038/s41572-022-00347-9
PMID:35393446
Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia despite substantial efforts to understand the pathophysiology of the condition and develop improved treatments. Identifying the underlying causative mechanisms of AF in individual patients is difficult and the efficacy of current therapies is suboptimal. Consequently, the incidence of AF is steadily rising and there is a pressing need for novel therapies. Research has revealed that defects in specific molecular pathways underlie AF pathogenesis, resulting in electrical conduction disorders that drive AF. The severity of this so-called electropathology correlates with the stage of AF disease progression and determines the response to AF treatment. Therefore, unravelling the molecular mechanisms underlying electropathology is expected to fuel the development of innovative personalized diagnostic tools and mechanism-based therapies. Moreover, the co-creation of AF studies with patients to implement novel diagnostic tools and therapies is a prerequisite for successful personalized AF management. Currently, various treatment modalities targeting AF-related electropathology, including lifestyle changes, pharmaceutical and nutraceutical therapy, substrate-based ablative therapy, and neuromodulation, are available to maintain sinus rhythm and might offer a novel holistic strategy to treat AF.

摘要

尽管在理解房颤的病理生理学和开发改进的治疗方法方面付出了巨大努力,但房颤仍然是最常见的心律失常。确定个体患者房颤的潜在病因机制很困难,而且目前的治疗效果并不理想。因此,房颤的发病率稳步上升,迫切需要新的治疗方法。研究表明,特定分子途径的缺陷是房颤发病机制的基础,导致电传导障碍,从而引发房颤。这种所谓的电病理严重程度与房颤疾病进展的阶段相关,并决定了房颤治疗的反应。因此,揭示电病理的分子机制有望为创新的个性化诊断工具和基于机制的治疗方法的发展提供动力。此外,与患者共同开展房颤研究以实施新的诊断工具和治疗方法是成功进行个性化房颤管理的前提。目前,有多种针对房颤相关电病理的治疗方法,包括生活方式改变、药物和营养疗法、基于基质的消融治疗和神经调节,可维持窦性节律,并可能为治疗房颤提供一种新的整体策略。

相似文献

1
Atrial fibrillation.心房颤动。
Nat Rev Dis Primers. 2022 Apr 7;8(1):21. doi: 10.1038/s41572-022-00347-9.
2
Clinical Relevance of Sinus Rhythm Mapping to Quantify Electropathology Related to Atrial Fibrillation.窦性心律标测对量化与心房颤动相关的电病理学的临床意义。
Arrhythm Electrophysiol Rev. 2022 Apr;11:e11. doi: 10.15420/aer.2022.03.
3
Dissecting the Molecular Mechanisms Driving Electropathology in Atrial Fibrillation: Deployment of RNA Sequencing and Transcriptomic Analyses.解析驱动心房颤动电生理学的分子机制:RNA 测序和转录组分析的应用。
Cells. 2023 Sep 9;12(18):2242. doi: 10.3390/cells12182242.
4
Atrial fibrillation fingerprinting; spotting bio-electrical markers to early recognize atrial fibrillation by the use of a bottom-up approach (AFFIP): Rationale and design.心房颤动特征分析;通过自下而上的方法(AFFIP)利用生物电标志物早期识别心房颤动:原理与设计。
Clin Cardiol. 2020 Jun;43(6):546-552. doi: 10.1002/clc.23370. Epub 2020 Apr 18.
5
Diagnosis and Therapy of Atrial Fibrillation: The Past, The Present and The Future.心房颤动的诊断与治疗:过去、现在与未来
J Atr Fibrillation. 2015 Aug 31;8(2):1216. doi: 10.4022/jafib.1216. eCollection 2015 Aug-Sep.
6
Long Noncoding RNA UCA1 Correlates With Electropathology in Patients With Atrial Fibrillation.长链非编码 RNA UCA1 与房颤患者电生理学相关。
JACC Clin Electrophysiol. 2023 Jul;9(7 Pt 2):1097-1107. doi: 10.1016/j.jacep.2023.02.018. Epub 2023 May 24.
7
The Role of Immune Cells Driving Electropathology and Atrial Fibrillation.免疫细胞在电生理学和心房颤动中的作用。
Cells. 2024 Feb 8;13(4):311. doi: 10.3390/cells13040311.
8
Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it.为什么将基础发现转化为房颤的临床应用如此困难,以及改善这种情况的可能方法。
Cardiovasc Res. 2021 Jun 16;117(7):1616-1631. doi: 10.1093/cvr/cvab093.
9
Intra-operative mapping of the atria: the first step towards individualization of atrial fibrillation therapy?心房的术中标测:迈向房颤治疗个体化的第一步?
Expert Rev Cardiovasc Ther. 2017 Jul;15(7):537-545. doi: 10.1080/14779072.2017.1340156. Epub 2017 Jun 15.
10
Prevention of Atrial Fibrillation: Putting Proteostasis Derailment Back on Track.心房颤动的预防:使蛋白质稳态失衡重回正轨
J Clin Med. 2023 Jun 28;12(13):4352. doi: 10.3390/jcm12134352.

引用本文的文献

1
Association between fibrinogen-to-albumin ratio and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study using the MIMIC-IV database.房颤危重症患者纤维蛋白原与白蛋白比值和全因死亡率的关联:一项使用MIMIC-IV数据库的回顾性研究
Eur J Med Res. 2025 Aug 29;30(1):822. doi: 10.1186/s40001-025-03101-5.
2
Early menopause as an independent risk factor for postoperative atrial fibrillation in women undergoing coronary artery bypass grafting: a retrospective cohort study.早期绝经作为冠状动脉搭桥术女性患者术后心房颤动的独立危险因素:一项回顾性队列研究。
BMC Womens Health. 2025 Aug 28;25(1):411. doi: 10.1186/s12905-025-03941-7.
3

本文引用的文献

1
Cardiovascular considerations in management of patients with Turner syndrome.特纳综合征患者管理中的心血管问题
Trends Cardiovasc Med. 2023 Apr;33(3):150-158. doi: 10.1016/j.tcm.2021.12.002. Epub 2021 Dec 11.
2
Comparative Effectiveness of Early Rhythm Control Versus Rate Control for Cardiovascular Outcomes in Patients With Atrial Fibrillation.早期节律控制与心率控制对房颤患者心血管结局的比较效果。
J Am Heart Assoc. 2021 Dec 21;10(24):e023055. doi: 10.1161/JAHA.121.023055. Epub 2021 Dec 10.
3
Stroke prevention in atrial fibrillation: comparison of recent international guidelines.
Horse model of spontaneous atrial fibrillation share proteomic changes with humans.
自发性心房颤动的马模型与人类存在蛋白质组学变化上的共性。
Sci Rep. 2025 Aug 28;15(1):31694. doi: 10.1038/s41598-025-16885-7.
4
Predictive value of ibutilide response for postoperative recurrence following catheter ablation in persistent atrial fibrillation: a retrospective study.伊布利特反应对持续性心房颤动导管消融术后复发的预测价值:一项回顾性研究
Front Cardiovasc Med. 2025 Aug 6;12:1623043. doi: 10.3389/fcvm.2025.1623043. eCollection 2025.
5
The impact of cardiac rehabilitation exercises incorporating music movement therapy on atrial fibrillation patients: a forward-looking investigation.结合音乐运动疗法的心脏康复锻炼对心房颤动患者的影响:一项前瞻性研究。
J Cardiothorac Surg. 2025 Aug 19;20(1):341. doi: 10.1186/s13019-025-03582-9.
6
The senescence-inducing factor IGFBP7 and risk of atrial fibrillation: findings from the PREVEND study.衰老诱导因子IGFBP7与心房颤动风险:PREVEND研究的结果
NPJ Cardiovasc Health. 2025;2(1):42. doi: 10.1038/s44325-025-00079-1. Epub 2025 Aug 12.
7
Atrial fibrillation and flutter conversion with pulsed electric field delivery: preclinical proof of concept.脉冲电场传导用于心房颤动和扑动的转复:临床前概念验证
J Interv Card Electrophysiol. 2025 Aug 14. doi: 10.1007/s10840-025-02115-7.
8
Adipose stem cell-derived exosomes circular RNA circFryl attenuate atrial fibrosis and cardiomyocyte apoptosis in atrial fibrillation.脂肪干细胞来源的外泌体环状RNA circFryl减轻心房颤动中的心房纤维化和心肌细胞凋亡。
Iran J Basic Med Sci. 2025;28(9):1180-1189. doi: 10.22038/ijbms.2025.84766.18341.
9
Aging-associated mechanisms of atrial fibrillation progression and their therapeutic potential.心房颤动进展的衰老相关机制及其治疗潜力。
J Cardiovasc Aging. 2024 Dec;4(4). doi: 10.20517/jca.2024.12. Epub 2024 Nov 7.
10
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Valve Replacement: An Umbrella Review.心房颤动合并生物瓣膜置换患者中直接口服抗凝剂与维生素K拮抗剂的比较:一项伞状综述
J Innov Card Rhythm Manag. 2025 Jul 15;16(7):6355-6373. doi: 10.19102/icrm.2025.16075. eCollection 2025 Jul.
心房颤动的卒中预防:近期国际指南比较
Eur Heart J Suppl. 2020 Dec 22;22(Suppl O):O53-O60. doi: 10.1093/eurheartj/suaa180. eCollection 2020 Dec.
4
Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial.常规出血风险评估与出血结局改善相关:mAFA-II 随机试验。
Am J Med. 2020 Oct;133(10):1195-1202.e2. doi: 10.1016/j.amjmed.2020.03.019. Epub 2020 Apr 12.
5
PREvention of recurrent arrhythmias with Mediterranean diet (PREDIMAR) study in patients with atrial fibrillation: Rationale, design and methods.预防心房颤动患者的复发性心律失常的地中海饮食(PREDIMAR)研究:原理、设计和方法。
Am Heart J. 2020 Feb;220:127-136. doi: 10.1016/j.ahj.2019.10.009. Epub 2019 Oct 26.
6
High Prevalence of Proarrhythmic Events in Patients With History of Atrial Fibrillation Undergoing a Rhythm Control Strategy: A Retrospective Study.采用节律控制策略的房颤病史患者中致心律失常事件的高发生率:一项回顾性研究
J Clin Med Res. 2019 May;11(5):345-352. doi: 10.14740/jocmr3805. Epub 2019 Apr 14.
7
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.非维生素 K 口服抗凝剂与苯丙香豆素在老年和非老年非瓣膜性心房颤动患者中的比较。
Thromb Haemost. 2019 Jun;119(6):971-980. doi: 10.1055/s-0039-1683422. Epub 2019 Mar 21.
8
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.51,000 例有卒中风险的房颤患者一年内口服抗凝治疗的变化:一项源自实践的研究。
Thromb Haemost. 2019 Jun;119(6):882-893. doi: 10.1055/s-0039-1683428. Epub 2019 Mar 21.
9
Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation.突变型 KCNJ3 和 KCNJ5 钾通道作为缓慢性心律失常和心房颤动的新分子靶点。
Circulation. 2019 Apr 30;139(18):2157-2169. doi: 10.1161/CIRCULATIONAHA.118.036761.
10
PREDIMED trial of Mediterranean diet: retracted, republished, still trusted?地中海饮食的PREDIMED试验:撤回、重新发表,仍值得信赖吗?
BMJ. 2019 Feb 7;364:l341. doi: 10.1136/bmj.l341.